medicinal chemistry

A1 BioChem Labs (ABCL), a subsidiary of Apitoria Pharma Private LTD, is a CRDMO offering comprehensive chemistry services to pharma, biotech, and academia. It operates advanced labs in Wilmington, NC, and Hyderabad, India, specializing in custom synthesis, medicinal chemistry, route scouting, analytical development, and commercial-scale manufacturing across FDA, EDQM, and PMDA approved sites.

analytical developmentchemical sourcingchiral analysisCMC supportcommercial-scale manufacturingcustom synthesisDMPKflow chemistrygenotoxic impurity assessmenthigh-vacuum distillationhydrogenationnitrosamine controlparticle-size distributionpolymorphismpowder processingprocess developmentprocess safetyroute scoutingsolid-state analysis

AACT, Inc. is a research-and-development-stage biopharmaceutical company focused on oncology, developing small-molecule, patent-protected drugs that exploit biological differences between tumor and normal cells. Its technology derives from research at the Icahn School of Medicine at Mount Sinai and the Fels Institute for Cancer Research and Molecular Biology of Temple University School of Medicine. Lead candidates include AA150030 and AA108600. AACT also runs an antiviral program developing broad-spectrum host-directed antivirals.

drug discoverykinase inhibitor developmentnebulized pulmonary drug deliverypreclinical testing

AAPharmaSyn is a US-based contract research organization (CRO) providing synthetic and medicinal chemistry services to pharmaceutical and biotechnology clients since 2006. Services include custom chemical synthesis, medicinal chemistry, custom lipid synthesis, stable isotope labeled compounds, process research and development, and project management support.

analytical supportasymmetric synthesischiral resolutionconjugation chemistrycustom synthesisisotope labelinglipid synthesismulti-step synthesisprocess chemistrypurification and characterizationroute scoutingscale-up/pilot synthesis

Acme Bioscience, Inc., a Frontage Company, is a chemistry CRO (contract research organization) established in 2001 in California, USA, with China operations in Shanghai since 2009. It provides discovery chemistry, medicinal chemistry, process chemistry research & development, and chemical manufacturing services for biopharmaceutical companies worldwide, with experience in antiviral and anti-bacterial research.

analytical services (HPLC, LCMS, NMR, X-ray, chiral analysis and separation)chemical manufacturingchiral synthesis and chiral separationFTE servicesprocess chemistry research & developmentroute selection and optimizationsynthetic chemistry

Akagera Medicines is a private Delaware-registered company founded in 2018 in Kigali, Rwanda, that develops novel and patented liposomal formulations of antibacterial drugs to treat tuberculosis and other infectious diseases. It is majority-owned by the people of Rwanda and has laboratories in Boston and San Francisco, plus a 100%-owned subsidiary in Kigali registered in 2022 for future manufacturing and clinical trials.

clinical trialsdrug deliveryin vitro testingliposomal formulationmanufacturing (planned)pre-clinical studiessmall-molecule drug engineering

ALIGOS Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH). The company targets liver and viral diseases with best-in-class therapies, leveraging medicinal chemistry and biology teams to build a differentiated pipeline.

biology researchdrug developmentdrug discovery

Altoris accelerates therapeutics discovery with intuitive software and analytics for small molecules. It supports biotechnology, pharmaceutical, and academic groups with desktop and enterprise tools developed in close collaboration with customers in complex research environments. Altoris combines proven software with custom development and consulting to help teams move faster from early discovery to preclinical work.

chemoinformaticscustom analytics and integrationmodeling and data workflowsmolecular informatics softwareScientific Consultingscreening library designstructural biology

AN2 Therapeutics is a clinical-stage biopharmaceutical company using a boron-based discovery platform to discover and develop medicines for infectious diseases and cancer. Its pipeline includes programs in polycythemia vera, Chagas disease, M. abscessus, and oncology targets PI3K and ENPP1, with lead compound epetraborole. The company is headquartered in Menlo Park, California.

boron-based drug discovery platformclinical developmentdrug discovery and development

Anviron is a University Co-founded team of oncologists and biochemists specialized in glycome oncology, founded in 2020 and based in Newport Beach, California. The company develops small molecule inhibitors of proteins responsible for proliferation signaling and metastasis, including drug candidates ANV221 and ANV322 for pancreatic cancer and advanced, drug-resistant HER2-positive breast cancer.

drug discoveryglycome oncology researchoncology therapeutics development

Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Its approach enables selective modulation of disease-causing proteins. The company is advancing multiple programs, including its lead asset ATV-1601, an oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT), and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms. It has built a versatile discovery platform that identifies functional pockets across protein classes, with an internal focus on rare

allosteric drug discoverycheminformaticsclinical developmentCMCDMPKRegulatory Affairstranslational research

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel Disease and other inflammatory diseases. It has developed a drug discovery and development platform that integrates medicinal chemistry and systems biology through machine learning to identify and develop novel drugs for patients with autoimmune and chronic inflammatory diseases.

computational medicinal chemistrydrug discovery and developmentmachine learningsmall molecule synthesissystems biology

Atomic AI operates at the intersection of artificial intelligence and RNA therapeutics, using machine learning and structural biology to develop RNA-centric medicines. Its proprietary R&D platform leverages ATOM-1, a foundation model for RNA that delivers precise predictions of RNA structure and function, integrated with in-house wet-lab assays. The company focuses on designing foundation models for RNA and developing RNA-targeted small molecules and RNA-based therapeutics.

drug discoverymachine learningRNA structure and function predictionstructural biologywet-lab assays

BioAscent is a provider of integrated drug discovery services based at the former Organon/MSD R&D site in Newhouse, Scotland, UK. Founded in 2013, its services include assay development, target analysis, compound screening, medicinal and synthetic chemistry, computational chemistry, DMPK, protein science and compound management, with access to in-house diversity and fragment libraries.

assay developmentbiophysicscompound managementcompound screeningcompound storage and logisticscomputational chemistryDMPKhigh throughput screeningin silico discoveryLC-MSliquid handlingNMRprotein productionpurificationstructural biologysurface plasmon resonancesynthetic chemistry

Broad Capabilities. Boutique Services. Every program deserves a partner, not just a provider. We built Bio Duro to be exactly the right size: broad enough to support your science at every stage, agile enough to move when you need to move, and focused enough to treat your program like the priority it is. Explore Our Capabilities All Company News October 1, 2026 June 6, 2026 May 28, 2026 April 28, 2026 April 23, 2026 March 12, 2026 March 3, 2026 February 10, 2026 January 27, 2026 November 18, 2025 August 20, 2025 July 30, 2025 June 10, 2025 May 8, 2025 April 7, 2025 March 25, 2025 March 5, 2025 January 20, 2025 January 9, 2025 January 6, 2025 October 24, 2024 October 1, 2024 September 16, 2024 All Company News Deliver solutions using enabling technologies like AI enabled molecular design, high throughput screening, DNA-coded library, parallel synthesis. Explore Chemistry Most visited.

AI-assisted molecular designanalytical chemistryAPI manufacturingbioanalysiscomputational chemistryDMPKDNA-encoded library screeningdrug product manufacturingformulation developmenthigh throughput screeningin vitro assaysin vivo modelsparallel synthesispeptide chemistryprocess R&DScale upsynthetic chemistrytoxicology

CalChem Synthesis is a US-based Contract Research Organization (CRO) providing chemistry services to biotech and pharmaceutical companies, research institutions, and cosmetic and nutraceutical companies. Founded by Dr. Jalal Haddad, the company offers custom synthesis of organic molecules, process research and development, scale-up, and sourcing and procurement services. Its chemistry activities are directed by Ph.D. level organic chemists with combined 35 years of experience.

analytical method developmentcustom synthesisprocess research and developmentScale upsourcing and procurementsynthesis of building blocks, intermediates, APIs, and drug conjugatessynthesis of process impurities, metabolites, and reference compoundssynthesis of toxicology batchestechnology transfer reports

Cellarity is a drug discovery company that aims to solve complex diseases with medicines designed to correct the dynamic cell state. Its integrated multi-omics and AI-powered discovery platform maps networks of cell and gene interactions to predict and design oral Cell State-Correcting therapeutics that regulate gene switch mechanisms to restore proper cell function. Cellarity was launched by Flagship Pioneering in 2019.

Artificial Intelligence and Machine Learningcomputational biologydrug discoverymulti-omics

Celyra Therapeutics is a preclinical biotechnology company developing modular small-molecule scaffold systems for intracellular delivery. Its compounds act on the cell's own trafficking machinery to induce bulk uptake of large payloads and hold open the point at which cargo would otherwise be committed to degradation, then the effect reverses. The platform is cargo-agnostic, having enhanced cytosolic access for proteins, antibodies, oligonucleotides and nanoparticles.

intracellular traffickinglipid nanoparticle engineeringphosphoinositide biology

ChemDiv is a fully integrated target-to-clinic contract research organization (CRO) that has worked for over 32 years on drug discovery programs for cancer, neurological, infectious, cardiometabolic and immune diseases with pharma, biotech and academic partners. It offers integrated drug discovery services including custom chemistry, HTS, CADD, ADME, DMPK, discovery biology and preclinical services.

ADME/DMPK testinganimal modelscombinatorial chemistrycustom chemistryhigh throughput screening (HTS)in silico drug design (CADD)in vitro assaysin vivo studieslibrary designmolecular dockingmolecular dynamicspharmacokinetic studiestoxicology studiesvirtual screening

ChemoGenics BioPharma is a drug discovery research and service organization providing preclinical drug discovery services to pharmaceutical, biotechnology, academic and government institutions globally. It has facilities in the Research Triangle Park Area in the United States and serves clients in the U.S. and Europe. Its core team has 10+ years of experience in preclinical drug discovery, with strengths in medicinal chemistry, cheminformatics, bioinformatics, ADMET and in vivo pharmacology in metabolic disease, oncology and inflammation.

analytical chemistryBioinformaticscGMP manufacturing of APIcheminformaticscloningcomputer-aided drug designcustom synthesisin vitro ADMEIn vivo PK/PDmolecular modelingProcess optimization and scale upRecombinant protein synthesis

Concarlo Therapeutics is a biotech company developing novel therapeutics to improve outcomes for cancer patients, using innovation in p27 biology. It is described as the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance. Its mission is to improve outcomes for patients with drug-resistant cancers by creating transformative therapies that control the p27 target.

computational biologydrug discoverypeptide therapeuticspreclinical development

Courage Therapeutics is a neuroendocrine company co-founded by Dr. Roger Cone that translates discoveries and novel chemistries into therapeutic candidates targeting the MC4R receptor. Its lead candidate, CTX-B, is a weekly injectable for the treatment of melanocortin-4 receptor haploinsufficiency (MC4R HI), a genetic obesity with no approved targeted therapeutic options.

drug discoveryIND-enabling programspreclinical development

Degromics Bio, Inc. is a company whose mission is to apply an innovative approach to help patients with well-defined cancer drivers by targeting the entire protein, aiming to overcome past failures with a new approach.

drug discoverytranslational cancer biology

DermaXon is a Montana-based drug discovery and development company founded in 2013 providing first-in-class drug candidates. It targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic disorders of skin keratinization. Its core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology.

drug discovery and developmentmolecular biologyRNA sequencingsmall molecule design and development

Dialectic Therapeutics is a clinical-stage biotechnology company based in Dallas, Texas, dedicated to developing innovative anti-cancer drugs. Its lead candidate, DT2216, is built on its proprietary Antiapoptotic Protein Targeted Degradation (APTaD™) technology platform and selectively induces cancer cells to degrade BCL-XL. DT2216 is in Phase 1/2 clinical trials for Fibrolamellar Carcinoma and Platinum-Resistant Ovarian Cancer.

clinical trialsdrug developmentprotein degradation